Caseware UK (AP4) 2025.0.111 2025.0.111 2025-12-312025-12-311false2025-06-12true0truetrue 16512963 2025-06-11 16512963 2025-06-12 2025-12-31 16512963 2024-01-01 2025-06-11 16512963 2025-12-31 16512963 c:Director1 2025-06-12 2025-12-31 16512963 d:CurrentFinancialInstruments 2025-12-31 16512963 d:ShareCapital 2025-12-31 16512963 c:OrdinaryShareClass1 2025-06-12 2025-12-31 16512963 c:OrdinaryShareClass1 2025-12-31 16512963 c:EntityHasNeverTraded 2025-06-12 2025-12-31 16512963 c:FRS102 2025-06-12 2025-12-31 16512963 c:AuditExempt-NoAccountantsReport 2025-06-12 2025-12-31 16512963 c:FullAccounts 2025-06-12 2025-12-31 16512963 c:PrivateLimitedCompanyLtd 2025-06-12 2025-12-31 16512963 e:PoundSterling 2025-06-12 2025-12-31 xbrli:shares iso4217:GBP xbrli:pure
Registered number: 16512963









EOCENE THERAPEUTICS LIMITED

UNAUDITED

FINANCIAL STATEMENTS
INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE PERIOD ENDED 31 DECEMBER 2025

 
EOCENE THERAPEUTICS LIMITED
REGISTERED NUMBER: 16512963

BALANCE SHEET
AS AT 31 DECEMBER 2025

2025
Note
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
1

  

Net assets
  
1


Capital and reserves
  

Called up share capital 
 5 
1

  
1


For the period ended 31 December 2025 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
Mr A J Baharaff
Director

Date: 24 September 2026

The notes on page 2 form part of these financial statements.

Page 1

 
EOCENE THERAPEUTICS LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025

1.


General information

Eocene Therapeutics Limited is a private company limited by shares incorporated in England and Wales within the United Kingdom. The address of the registered office is 3rd Floor, 24 Old Bond Street, London, United Kingdom, W1S 4AP. The Company is not part of a group.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.


3.


Employees

The average monthly number of employees, including directors, during the period was 1.


4.


Debtors

2025
£


Called up share capital not paid
1

1



5.


Share capital

2025
£
Allotted, called up and partly paid


1 Ordinary share of £1.00
1

1 Ordinary share with a nominal value of £1 was allotted during the period.


Page 2